EpicentRx

EpicentRx, based in La Jolla, the United States, is a biotechnology company. EpicentRx is a clinical-stage company developing therapies for inflammatory diseases and supportive care conditions, including an oncolytic virus immunotherapy and a small molecule for treatment-related toxicities. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3) in sarcomas, head and neck squamous cell carcinoma, small-cell lung cancer and non-small-cell lung cancer. The largest, NCT05566041 (A Phase 3, Controlled, Open-label, Global Randomised Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer), plans to enrol 292 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.